Scholarlink

Purpose <p>Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with antiresorptive and antiangiogenic therapies, particularly in oncology patients. Ozone therapy has been proposed as a supportive treatment due to its antimicrobial and tissue-regenerative properties, but its clinical efficacy remains uncertain.</p> Methods <p>This systematic review and meta-analysis, registered in PROSPERO (CRD42025631661), followed PRISMA 2020 guidelines. A comprehensive search was conducted in PubMed, Embase, Scopus, Web of Science, Cochrane Library, and gray literature. We included clinical studies using ozone therapy in adults with MRONJ. Studies combining ozone with other experimental interventions were excluded. Data on patient characteristics, protocols, and outcomes were extracted. A meta-analysis of proportions was performed using a random-effects model with logit transformation and Hartung-Knapp adjustment. Risk of bias was assessed using Joanna Briggs Institute tools.</p> Results <p>Six studies involving 178 patients (65.7% female; mean age ~ 65.9&#xa0;years) were included. Ozone therapy was administered in gaseous or oil-based formulations, with varied frequencies and application methods. The pooled clinical success rate was 71% (95% CI: 55%–84%), with moderate heterogeneity (I<sup>2</sup> = 41.9%). Sensitivity analyses confirmed the robustness of the results. No adverse effects were reported. Improvements in pain and quality of life were frequently observed. All studies were classified as having low risk of bias.</p> Conclusions <p>Ozone therapy may be associated with clinical benefits in MRONJ management. However, the evidence is of very low certainty due to methodological limitations and heterogeneity. Randomized clinical trials with standardized protocols are needed to clarify its role in supportive care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ozone therapy as an adjunctive strategy for MRONJ in oncology patients: A systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月11日

查看全文
  • Mailon Cury Carneiro,
  • Júlia França da Silva,
  • Tiago Carvalho dos Santos,
  • Camila Lopes Cardoso,
  • Paulo Sérgio da Silva Santos

摘要

Purpose

Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with antiresorptive and antiangiogenic therapies, particularly in oncology patients. Ozone therapy has been proposed as a supportive treatment due to its antimicrobial and tissue-regenerative properties, but its clinical efficacy remains uncertain.

Methods

This systematic review and meta-analysis, registered in PROSPERO (CRD42025631661), followed PRISMA 2020 guidelines. A comprehensive search was conducted in PubMed, Embase, Scopus, Web of Science, Cochrane Library, and gray literature. We included clinical studies using ozone therapy in adults with MRONJ. Studies combining ozone with other experimental interventions were excluded. Data on patient characteristics, protocols, and outcomes were extracted. A meta-analysis of proportions was performed using a random-effects model with logit transformation and Hartung-Knapp adjustment. Risk of bias was assessed using Joanna Briggs Institute tools.

Results

Six studies involving 178 patients (65.7% female; mean age ~ 65.9 years) were included. Ozone therapy was administered in gaseous or oil-based formulations, with varied frequencies and application methods. The pooled clinical success rate was 71% (95% CI: 55%–84%), with moderate heterogeneity (I2 = 41.9%). Sensitivity analyses confirmed the robustness of the results. No adverse effects were reported. Improvements in pain and quality of life were frequently observed. All studies were classified as having low risk of bias.

Conclusions

Ozone therapy may be associated with clinical benefits in MRONJ management. However, the evidence is of very low certainty due to methodological limitations and heterogeneity. Randomized clinical trials with standardized protocols are needed to clarify its role in supportive care.